NUCANA Aktie

>NUCANA Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>NUCANA Aktie

Name:

NUCANA ADR NEW LS-,04

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US67022C3043 / A41DTP

Symbol/ Ticker:

N040 (Frankfurt)

Kürzel:

FRA:N040, ETR:N040, N040:GR

Index:

Webseite:

https://www.nucana.com/

Profil:

Marktkapitalisierung:

5.55 Mio. EUR

Unternehmenswert:

-21.92 Mio. EUR

Umsatz:

EBITDA:

-23.63 Mio. EUR

Nettogewinn:

-33.78 Mio. EUR

Gewinn je Aktie:

-116.61 EUR

Schulden:

0.79 Mio. EUR

Liquide Mittel:

28.26 Mio. EUR

Operativer Cashflow:

-8.15 Mio. EUR

Bargeldquote:

5.06

Umsatzwachstum:

Gewinnwachstum:

-61.13%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NUCANA

Letzte Datenerhebung:

04.04.26

>NUCANA Kennzahlen

Aktien/ Unternehmen:

Aktien: 4.16 Mio. St.

Frei handelbar: 93.01%

Leerverk. Aktien: -

Rückkaufquote: -572.04%

Mitarbeiter: 12

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 0.36

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -133%

Eigenkaprendite: -194.09%

>NUCANA Peer Group

Gesundheit

>NUCANA Chart & Kurs - Stuttgart

>NUCANA News

19.03.26 - 21:18	NuCana GAAP EPS of $0.00 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.26 - 21:03	NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma...

06.01.26 - 15:12	NuCana appoints Theresa Bruce as chief operating officer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.12.25 - 14:03	NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma (GlobeNewswire EN)
	Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings...

13.11.25 - 22:57	NuCana GAAP EPS of £0.00 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 22:03	NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Announced Encouraging Data on both NUC-7738 and NUC-3373...

05.11.25 - 14:30	NuCana: Aktie steigt nach Erteilung von Schlüsselpatent für Krebsmedikament in China (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 14:03

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China (GlobeNewswire EN)

EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738. This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana's novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study (NuTide:701) in combination with pembrolizumab for patients with PD-1 inhibitor refractory or resistant melanoma. Securing this patent represents an important milestone for NuCana, strengthening its long-term global intellectual property strategy, while supporting potential opportunities to address unmet needs for innovative cancer therapies in China....

18.10.25 - 14:03	NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 (GlobeNewswire EN)
	NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death...

05.09.25 - 15:21	NuCana receives compliance notification from Nasdaq (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.09.25 - 14:03	NuCana Compliant with All Nasdaq Continued Listing Criteria (GlobeNewswire EN)
	Anticipated Cash Runway into 2029 Anticipated Cash Runway into 2029...

03.09.25 - 14:03	NuCana to Present Data on NUC-7738′s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 (GlobeNewswire EN)
	EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”)....

20.08.25 - 22:09	NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma...

11.08.25 - 08:36	XFRA: N040: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL NUCANA ADR NEW LS-,04 N040 US67022C3043 BAW/UFN...

11.08.25 - 08:01	XFRA: INSTRUMENT_SUSPENSION - US67022C3043 (XETRA)
	Instrument ID [25039604] (N040 - US67022C3043) suspended...

10.08.25 - 21:36	XFRA: NEW INSTRUMENT AVAILABLE - 11.08.2025 - US67022C3043 (XETRA)
	Das Instrument N040 US67022C3043 NUCANA ADR NEW LS-,04 EQUITY hat seinen ersten Handelstag am 11.08.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument N040 US67022C3043 NUCANA ADR NEW LS-,04 EQUITY has its first trading date on 11.08.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...

08.08.25 - 16:46	XFRA: ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA8959792018 Trilogy AI Corp. 08.08.2025 CA88909Q1090 TOKENWELL PLATFORMS INC. 11.08.2025 Tausch 1:1 US92536C1036 Veru Inc. 08.08.2025 US92536C2026 Veru Inc. 11.08.2025 Tausch 10:1 US67022C2052 Nucana PLC 08.08.2025 US67022C3043 Nucana PLC 11.08.2025 Tausch 200:1...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram